Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long.Since reaching a peak last May, Moderna stock has tumbled by about 79%, and investors are starting to wonder if it could be a bargain now.Here's a look at what's been pressuring the formerly high-flying biotech stock to see if it can bounce back from the severe beating it's received over the past several months.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool